Abstract

Background: Portal vein tumor thrombus plays an important role in indicating the poor prognosis of hepatocellular carcinoma.
Purpose: To assess the safety and efficiency of iodine-125 seed combined with stent placement and transarterial chemoembolization for treatment of hepatocellular carcinoma with portal vein tumor thrombosis.
Materials and methods: We searched Cochrane library, PubMed, EMBASE, CNKI, Wang fang Data and CQVIP. We assessed the qualities of included studies. We analyzed the characteristic data, tested heterogeneity, explored heterogeneity and tested publication bias by software-Review Manger 3.5.
Result: Totally 7 clinical controlled trials were selected with the inclusion criterion. The results showed that the pressure of main portal vein after stent placement was significantly lower than no stent placement. The cumulative stent patency rates and survival rates in 6 and 12 months of iodine-125 seed combined with stent placement and transarterial chemoembolization were higher than conventional transarterial chemoembolization, transarterial chemoembolization combined with stent and 3-dimensional conformal radiotherapy.
z Conclusion: For hepatocellular carcinoma patients with portal vein tumor thrombosis, iodine-125 seed combined with stent placement and transarterial chemoembolization was safety. The efficiency of iodine-125 seed combined with stent placement and transarterial chemoembolization were better than conventional transarterial chemoembolization, transarterial chemoembolization plus stent and transarterial chemoembolization combined with stent and 3-dimensional conformal radiotherapy.

Keywords:Hepatocellular carcinoma; Transarterial chemoembolization; Portal vein tumor thrombus; Stent; Iodine-125; Meta-analysis

Keywords:HCC: Hepatocellular Carcinoma; PVTT: Portal Vein Tumor Thrombus; TACE: Transarterial Chemoembolization; 3-DCRT: 3-Dimensional Conformal Radiotherapy; I125: Iodine-125